Intravenous immunoglobulin (IVIG) in the treatment of COVID-19-induced cytokine storm

Phase 3

Recruiting

• Conditions: Condition 1: COVID-19. Condition 2: Coronavirus (COVID-19)-induced pneumonia.; Pneumonia due to SARS-associated coronavirus; U07.1: COVID-19, virus identified; J12.81; U07.1

• Registration Number: IRCT20200317046797N3
• Lead Sponsor: Tabriz University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 18 May 2020

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 100

Inclusion Criteria

Respiratory rate more than 30
PaO2/FiO2 less than 300 mm Hg
Positive PCR for COVID -19
Age 18-65 year

Exclusion Criteria

Sensitivity to IVIG
Pregnancy
IgA deficiency syndrome

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Improving the general condition of the patient. Timepoint: Before and after intervention. Method of measurement: Lung CT scan; No need to receive any intensive respiratory care in the patient.;Mortality rate. Timepoint: At baseline and discharge time or patient death. Method of measurement: Observation.;Need for intubation. Timepoint: Period of hospitalization. Method of measurement: Observation or reading of hospitalized documents.